BeiGene Says Israeli Ministry Of Health Approved TEVIMBRA (Tislelizumab) As Monotherapy For Treatment Of Adult Patients With Unresectable Or Metastatic OESCC After Prior Systemic Chemotherapy
BeiGene Says Israeli Ministry Of Health Approved TEVIMBRA (Tislelizumab) As Monotherapy For Treatment Of Adult Patients With Unresectable Or Metastatic OESCC After Prior Systemic Chemotherapy
百濟神州表示，以色列衛生部已批准TEVIMBRA（Tislelizumab）作爲單藥治療不可切除或轉移性食道鱗狀細胞癌成人患者的先前全身化療後的治療
BeiGene Says Israeli Ministry Of Health Approved TEVIMBRA (Tislelizumab) As Monotherapy For Treatment Of Adult Patients With Unresectable Or Metastatic OESCC After Prior Systemic Chemotherapy
百濟神州表示，以色列衛生部已批准TEVIMBRA（Tislelizumab）作爲單藥治療不可切除或轉移性食道鱗狀細胞癌成人患者的先前全身化療後的治療
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間